Orphazyme A/S ADR (ORPH): Price and Financial Metrics


Orphazyme A/S ADR (ORPH): $0.87

-0.02 (-2.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ORPH Stock Price Chart Interactive Chart >

Price chart for ORPH

ORPH Price/Volume Stats

Current price $0.87 52-week high $77.77
Prev. close $0.89 52-week low $0.51
Day low $0.85 Volume 941,400
Day high $0.96 Avg. volume 1,371,185
50-day MA $1.51 Dividend yield N/A
200-day MA $3.77 Market Cap 30.72M

Orphazyme A/S ADR (ORPH) Company Bio


Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Mørkeberg Hinsby, Marja Jäättela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.


ORPH Latest News Stream


Event/Time News Detail
Loading, please wait...

ORPH Latest Social Stream


Loading social stream, please wait...

View Full ORPH Social Stream

Latest ORPH News From Around the Web

Below are the latest news stories about Orphazyme A that investors may wish to consider to help them evaluate ORPH as an investment opportunity.

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products

Yahoo | February 23, 2022

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 20

Yahoo | February 18, 2022

Resolutions passed at the Extraordinary General Meeting

Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting: Approved the authorizations to the Board of Directors and amendments to the articles of

Yahoo | February 15, 2022

Amendment of proposals put forward at the Extraordinary General Meeting

Orphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda o

Yahoo | February 14, 2022

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

Yahoo | February 14, 2022

Read More 'ORPH' Stories Here

ORPH Price Returns

1-mo N/A
3-mo -30.95%
6-mo -72.73%
1-year -84.46%
3-year N/A
5-year N/A
YTD -63.90%
2021 -77.54%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6833 seconds.